Diabetes Dialogue: Milestones for MiniMed 780G and Signos CGM for Weight Loss

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, breakdown recent diabetes technology updates from late August and early September 2025.

The first development discussed came from Medtronic—now branded as MiniMed—with the US Food and Drug Administration (FDA) clearance of its 780G automated insulin delivery (AID) system for adults with type 2 diabetes. While insulin pumps have long been used off-label in this population, official clearance expands access and allows company representatives to openly engage clinicians about pump use in type 2 diabetes.1

The hosts noted, however, reimbursement remains a key challenge, as Medicare coverage for pumps in type 2 diabetes is still limited. Nevertheless, data demonstrating improved time-in-range and A1C reductions make a compelling case for broader adoption.1

Another milestone for the 780G is its new interoperability designation, enabling integration with non-proprietary continuous glucose monitors (CGMs). This includes Abbott’s upcoming 15-day Libre sensor, Instinct, as well as Simplera, which is awaiting US launch. The ability to pair with widely used sensors could improve patient uptake, particularly among those already familiar with Libre technology.1

The episode also highlighted the FDA clearance of Signos, the first FDA-cleared CGM specifically indicated for weight management. Built on Dexcom’s Stelo hardware but paired with a proprietary app, Signos delivers educational modules, behavior prompts, and unique metrics such as “spikes per day” and “latest spike time.” Positioned as a tool for individuals with prediabetes or those seeking structured support for lifestyle changes, it functions as both a glucose monitor and a coaching platform, drawing comparisons to digital health programs like Noom.2

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

References:

1. Medtronic. FDA Clears MiniMedTM 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes. Medtronic. Published September 2, 2025. Accessed September 6, 2025. https://news.medtronic.com/2025-09-02-FDA-Clears-MiniMed-TM-780G-System-to-Enable-Integration-with-the-Instinct-Sensor,-Made-by-Abbott,-and-Approves-Use-in-Type-2-Diabetes

2. Signos. Signos Unveils First Ever FDA-Cleared Glucose Monitoring Breakthrough for Weight Management, Enabling Millions of Americans to Take Control of Their Health. Prnewswire.com. Published August 20, 2025. Accessed September 7, 2025. https://www.prnewswire.com/news-releases/signos-unveils-first-ever-fda-cleared-glucose-monitoring-breakthrough-for-weight-management-enabling-millions-of-americans-to-take-control-of-their-health-302534147.html